"Does this announcement just mean that Yale's involvement is now no longer required, now the drug development for clinical trials is over?
Yes I think you are correct with that rhetorical question if looking at why CanTx was set up; the fact the company now is looking to have in the clinical trials ovarian cancer patients as well as those with ascetes seems to indicate they have confidence in drug delivery vehicles for ovarian cancer so one extra good reason to keep holding this stock